Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MATTHEW B ZOOK

Allopathic & Osteopathic Physicians Dermatology

NPI
1275740391
CMS profile
102813
Location
LARGO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,705.56

78 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,705.56 78

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MATTHEW B ZOOK

NPI 1275740391 · CMS profile ID 102813

Allopathic & Osteopathic Physicians / Dermatology

LARGO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275740391?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MATTHEW B ZOOK, NPI 1275740391, CMS profile ID 102813. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275740391?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MATTHEW B ZOOK, NPI 1275740391, CMS profile ID 102813. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275740391?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MATTHEW B ZOOK, NPI 1275740391, CMS profile ID 102813, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1275740391?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

78 matching records · $1,705.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 78 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–78 of 78.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $22.2205/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796310165 CMS
Lilly USA, LLC $17.1405/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818668445 CMS
Genentech USA, Inc. $16.4505/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835948375 CMS
Novartis Pharmaceuticals Corporation $122.3705/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813389465 CMS
AbbVie Inc. $17.2805/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796310163 CMS
Lilly USA, LLC $15.8405/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818610229 CMS
Novartis Pharmaceuticals Corporation $16.6204/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813389497 CMS
GENZYME CORPORATION $22.3304/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843622025 CMS
Novartis Pharmaceuticals Corporation $21.5404/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813389493 CMS
Regeneron Healthcare Solutions, Inc. $27.1504/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809639143 CMS
Novartis Pharmaceuticals Corporation $9.8504/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813389489 CMS
Lilly USA, LLC $13.2803/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818656361 CMS
AbbVie Inc. $14.5603/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796310161 CMS
Novartis Pharmaceuticals Corporation $16.7703/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813389485 CMS
Amgen Inc. $26.6303/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826390027 CMS
Novartis Pharmaceuticals Corporation $17.0103/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813389477 CMS
VYNE Pharmaceuticals Inc. $19.2303/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830828789 CMS
LEO Pharma Inc. $23.3703/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842278591 CMS
Novartis Pharmaceuticals Corporation $21.4402/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813389481 CMS
Novartis Pharmaceuticals Corporation $15.2302/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813389473 CMS
PFIZER INC. $16.5202/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832633861 CMS
Galderma Laboratories, L.P. $14.2302/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855310701 CMS
Amgen Inc. $27.5302/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826390025 CMS
AbbVie Inc. $17.1502/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796310159 CMS
Lilly USA, LLC $20.4101/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818587147 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $15.9101/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851909653 CMS
Novartis Pharmaceuticals Corporation $19.1601/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813389469 CMS
Amgen Inc. $24.9601/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826390021 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,816.21 84
PY2020 $1,104.80 55
PY2021 $1,705.56 78
PY2022 $1,297.65 71
PY2023 $1,245.97 58
PY2024 $27,363.38 134
PY2025 $69,585.34 145

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $834,926.25 456
PY2024 Principal investigator $1,047,501.07 596
PY2023 Recipient $8,100.00 1
PY2023 Principal investigator $683,021.77 340
PY2022 Principal investigator $226,578.51 85
PY2021 Principal investigator $290,662.09 129
PY2020 Recipient $13.00 1
PY2020 Principal investigator $391,493.40 103
PY2019 Recipient $18,876.00 3
PY2019 Principal investigator $852,525.67 123

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

456 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $2,675.00 12/19/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498113
Principal investigator 1 Incyte Corporation $2,675.00 12/19/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498118
Principal investigator 1 Incyte Corporation $55.00 12/19/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498129
Principal investigator 1 Incyte Corporation $55.00 12/19/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498133
Principal investigator 1 Incyte Corporation $55.00 12/19/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498137
Principal investigator 1 Incyte Corporation $1,715.00 12/19/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498157
Principal investigator 1 Incyte Corporation $1,820.00 12/19/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498162
Principal investigator 1 Incyte Corporation $1,628.00 12/19/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498171
Principal investigator 1 Incyte Corporation $1,628.00 12/19/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498175
Principal investigator 1 Incyte Corporation $1,672.00 12/19/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498186
Principal investigator 1 Incyte Corporation $1,893.00 12/19/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498205
Principal investigator 1 Incyte Corporation $1,893.00 12/19/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498210
Principal investigator 1 Incyte Corporation $490.00 12/19/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570441
Principal investigator 1 Incyte Corporation $440.00 12/19/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570769
Principal investigator 1 Incyte Corporation $412.30 12/19/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240571041
Principal investigator 1 Incyte Corporation $2,667.00 12/10/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570825
Principal investigator 1 Incyte Corporation $2,667.00 12/10/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570829
Principal investigator 1 Incyte Corporation $6,146.55 12/08/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570451
Principal investigator 1 Incyte Corporation $4,440.00 12/04/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240498043
Principal investigator 1 Incyte Corporation $798.80 12/04/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240571046
Principal investigator 1 Incyte Corporation $2,052.95 12/04/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240571050
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,145.90 12/03/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLO
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223289184
Principal investigator 1 Hoffmann-La Roche Limited $2,719.00 12/01/2025 Non-covered Recipient Entity
Academic Alliance in Dermatology
VELARITE No dispute reported 06/30/2026 1211566274
Principal investigator 1 Hoffmann-La Roche Limited $3,223.00 12/01/2025 Non-covered Recipient Entity
Academic Alliance in Dermatology
VELARITE No dispute reported 06/30/2026 1211566279
Principal investigator 1 Incyte Corporation $21.33 12/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570427
Principal investigator 1 Incyte Corporation $24.66 12/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570457
Principal investigator 1 Incyte Corporation $24.66 12/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570462
Principal investigator 1 Incyte Corporation $24.66 12/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570467
Principal investigator 1 Incyte Corporation $24.66 12/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570471
Principal investigator 1 Incyte Corporation $137.40 12/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570476
Principal investigator 1 Incyte Corporation $6.36 12/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570488
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570496
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570502
Principal investigator 1 Incyte Corporation $30.81 12/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570542
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570559
Principal investigator 1 Incyte Corporation $47.40 12/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570640
Principal investigator 1 Incyte Corporation $48.54 12/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570671
Principal investigator 1 Incyte Corporation $9.48 12/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570712
Principal investigator 1 Incyte Corporation $9.48 12/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570716
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570727
Principal investigator 1 Incyte Corporation $11.85 12/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570746
Principal investigator 1 Incyte Corporation $11.85 12/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570748
Principal investigator 1 Incyte Corporation $11.85 12/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570753
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570796
Principal investigator 1 Incyte Corporation $55.00 12/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570803
Principal investigator 1 Incyte Corporation $18.96 12/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570821
Principal investigator 1 Incyte Corporation $75.00 11/25/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240571032
Principal investigator 1 Incyte Corporation $1,871.00 11/24/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570524
Principal investigator 1 Incyte Corporation $1,871.00 11/24/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570530
Principal investigator 1 Incyte Corporation $2,734.00 11/24/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570623
Principal investigator 1 Incyte Corporation $1,310.20 11/24/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570664
Principal investigator 1 Incyte Corporation $105.00 11/21/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498067
Principal investigator 1 Incyte Corporation $2,675.00 11/21/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498071
Principal investigator 1 Incyte Corporation $2,675.00 11/21/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498074
Principal investigator 1 Incyte Corporation $2,675.00 11/21/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498078
Principal investigator 1 Incyte Corporation $2,675.00 11/21/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498082
Principal investigator 1 Incyte Corporation $2,675.00 11/21/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498086
Principal investigator 1 Incyte Corporation $105.00 11/21/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498090
Principal investigator 1 Incyte Corporation $105.00 11/21/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498095
Principal investigator 1 Incyte Corporation $1,893.00 11/21/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498102
Principal investigator 1 Incyte Corporation $1,820.00 11/21/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498142
Principal investigator 1 Incyte Corporation $55.00 11/21/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498150
Principal investigator 1 Incyte Corporation $1,733.00 11/21/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498214
Principal investigator 1 Incyte Corporation $40.00 11/21/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570434
Principal investigator 1 Incyte Corporation $55.00 11/21/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570537
Principal investigator 1 Incyte Corporation $63.00 11/21/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570565
Principal investigator 1 Incyte Corporation $75.00 11/21/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570809
Principal investigator 1 Incyte Corporation $1,606.45 11/14/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240571026
Principal investigator 1 Incyte Corporation $126.00 11/12/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570700
Principal investigator 1 Incyte Corporation $220.00 11/12/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570706
Principal investigator 1 Incyte Corporation $110.00 11/12/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570739
Principal investigator 1 Incyte Corporation $1,952.00 11/10/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570676
Principal investigator 1 Incyte Corporation $1,952.00 11/10/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570682
Principal investigator 1 Incyte Corporation $412.30 11/07/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240571018
Principal investigator 1 Incyte Corporation $113.00 11/05/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498106
Principal investigator 1 Incyte Corporation $724.00 11/05/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498153
Principal investigator 1 Incyte Corporation $75.00 11/05/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498202
Principal investigator 1 Incyte Corporation $406.20 11/05/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570577
Principal investigator 1 Incyte Corporation $109.52 11/05/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570595
Principal investigator 1 ABBVIE INC. $3,394.65 11/04/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERM LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202520491
Principal investigator 1 Incyte Corporation $5,250.00 11/03/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498110
Principal investigator 1 Incyte Corporation $3,500.00 11/03/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498121
Principal investigator 1 Incyte Corporation $1,550.00 11/03/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498166
Principal investigator 1 Incyte Corporation $1,000.00 11/03/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498178
Principal investigator 1 Incyte Corporation $1,000.00 11/03/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498181
Principal investigator 1 Incyte Corporation $18,401.00 11/03/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498198
Principal investigator 1 Incyte Corporation $40.00 10/27/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570553
Principal investigator 1 Incyte Corporation $110.00 10/27/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570627
Principal investigator 1 Incyte Corporation $63.00 10/27/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570635
Principal investigator 1 Incyte Corporation $168.00 10/27/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570816
Principal investigator 1 Incyte Corporation $105.00 10/22/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498100
Principal investigator 1 Incyte Corporation $1,893.00 10/22/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498125
Principal investigator 1 Incyte Corporation $55.00 10/22/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498146
Principal investigator 1 Incyte Corporation $2,675.00 10/22/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498190
Principal investigator 1 Incyte Corporation $2,675.00 10/22/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240498194
Principal investigator 1 Incyte Corporation $1,191.80 10/20/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570446
Principal investigator 1 Incyte Corporation $497.00 10/20/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570547
Principal investigator 1 Incyte Corporation $2,734.00 10/20/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570601
Principal investigator 1 Incyte Corporation $1,871.00 10/20/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570607
Principal investigator 1 Incyte Corporation $1,871.00 10/20/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570611
Principal investigator 1 Incyte Corporation $1,871.00 10/20/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570617
Principal investigator 1 Incyte Corporation $1,433.00 10/16/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240498030
Principal investigator 1 ABBVIE INC. $1,482.20 10/09/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202514041
Principal investigator 1 Incyte Corporation $3,754.00 10/09/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240498025
Principal investigator 1 Incyte Corporation $93.00 10/09/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240498035
Principal investigator 1 Incyte Corporation $344.00 10/09/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240498039
Principal investigator 1 Incyte Corporation $126.00 10/08/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570507
Principal investigator 1 Incyte Corporation $2,667.00 10/08/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570583
Principal investigator 1 Incyte Corporation $160.00 10/08/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570653
Principal investigator 1 Incyte Corporation $220.00 10/08/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570657
Principal investigator 1 Incyte Corporation $300.00 10/08/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570733
Principal investigator 1 Incyte Corporation $75.00 10/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240571012
Principal investigator 1 Incyte Corporation $165.00 10/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570513
Principal investigator 1 Incyte Corporation $165.00 10/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570518
Principal investigator 1 Incyte Corporation $80.00 10/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570589
Principal investigator 1 Incyte Corporation $100.00 10/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570646
Principal investigator 1 Incyte Corporation $1,871.00 10/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570720
Principal investigator 1 Incyte Corporation $1,720.00 10/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570759
Principal investigator 1 Incyte Corporation $1,720.00 10/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570763
Principal investigator 1 Incyte Corporation $206.60 10/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570774
Principal investigator 1 Incyte Corporation $126.00 10/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570778
Principal investigator 1 Incyte Corporation $126.00 10/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570790
Principal investigator 1 Incyte Corporation $45.80 10/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570484
Principal investigator 1 Incyte Corporation $135.40 10/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570571
Principal investigator 1 Incyte Corporation $60.75 10/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570687
Principal investigator 1 Incyte Corporation $109.52 10/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570692
Principal investigator 1 Novartis Pharmaceuticals Corporation $140.00 10/01/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190311033
Principal investigator 1 PFIZER INC. $21,534.00 09/24/2025 Non-covered Recipient Entity
Olympian Clinical Research LLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228754081
Principal investigator 1 Incyte Corporation $4,393.00 09/23/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240498021
Principal investigator 1 Incyte Corporation $220.00 09/22/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570051
Principal investigator 1 Incyte Corporation $2,500.00 09/22/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570056
Principal investigator 1 Incyte Corporation $14,500.00 09/22/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570063
Principal investigator 1 Incyte Corporation $210.00 09/22/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570422
Principal investigator 1 Incyte Corporation $220.00 09/12/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570239
Principal investigator 1 Incyte Corporation $80.00 09/12/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570245
Principal investigator 1 Incyte Corporation $105.00 09/12/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570251
Principal investigator 1 Incyte Corporation $110.00 09/12/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570257
Principal investigator 1 Incyte Corporation $110.00 09/12/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570262
Principal investigator 1 Incyte Corporation $63.00 09/12/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570267
Principal investigator 1 Incyte Corporation $126.00 09/12/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570314
Principal investigator 1 Incyte Corporation $126.00 09/12/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570320
Principal investigator 1 Incyte Corporation $80.00 09/12/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570358
Principal investigator 1 Incyte Corporation $1,952.00 09/10/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570108
Principal investigator 1 Incyte Corporation $1,952.00 09/10/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570154
Principal investigator 1 Incyte Corporation $2,667.00 09/10/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570324
Principal investigator 1 Incyte Corporation $1,952.00 09/10/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570380
Principal investigator 1 Hoffmann-La Roche Limited $2,900.00 09/03/2025 Non-covered Recipient Entity
Academic Alliance in Dermatology
VELARITE No dispute reported 06/30/2026 1211566254
Principal investigator 1 Hoffmann-La Roche Limited $2,000.00 09/03/2025 Non-covered Recipient Entity
Academic Alliance in Dermatology
VELARITE No dispute reported 06/30/2026 1211566258
Principal investigator 1 Hoffmann-La Roche Limited $2,750.00 09/03/2025 Non-covered Recipient Entity
Academic Alliance in Dermatology
VELARITE No dispute reported 06/30/2026 1211566262
Principal investigator 1 Hoffmann-La Roche Limited $1,550.00 09/03/2025 Non-covered Recipient Entity
Academic Alliance in Dermatology
VELARITE No dispute reported 06/30/2026 1211566266
Principal investigator 1 Hoffmann-La Roche Limited $14,000.00 09/03/2025 Non-covered Recipient Entity
Academic Alliance in Dermatology
VELARITE No dispute reported 06/30/2026 1211566270
Principal investigator 1 Incyte Corporation $140.00 08/22/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570080
Principal investigator 1 Incyte Corporation $350.00 08/22/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570086
Principal investigator 1 Incyte Corporation $110.00 08/22/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570099
Principal investigator 1 Incyte Corporation $330.00 08/22/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570368
Principal investigator 1 Incyte Corporation $2,733.15 08/21/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240571006
Principal investigator 1 Incyte Corporation $113.05 08/20/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570091
Principal investigator 1 Incyte Corporation $1,720.00 08/20/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570114
Principal investigator 1 Incyte Corporation $1,720.00 08/20/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570122
Principal investigator 1 Incyte Corporation $1,871.00 08/20/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570128
Principal investigator 1 Incyte Corporation $1,871.00 08/20/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570133
Principal investigator 1 Novartis Pharmaceuticals Corporation $447.06 08/15/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190304553
Principal investigator 1 ABBVIE INC. $5,369.85 08/05/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERM LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202501248
Principal investigator 1 ABBVIE INC. $1,690.10 08/05/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202501250
Principal investigator 1 Incyte Corporation $270.80 08/04/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570165
Principal investigator 1 Incyte Corporation $2,667.00 08/04/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570214
Principal investigator 1 Incyte Corporation $1,952.00 08/04/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570233
Principal investigator 1 Incyte Corporation $80.90 08/04/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570272
Principal investigator 1 Incyte Corporation $64.72 08/04/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570279
Principal investigator 1 Incyte Corporation $49.36 08/04/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570285
Principal investigator 1 Incyte Corporation $20.14 08/04/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570290
Principal investigator 1 Incyte Corporation $186.81 08/04/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570297
Principal investigator 1 Incyte Corporation $125.95 08/04/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570303
Principal investigator 1 Incyte Corporation $91.60 08/04/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570307
Principal investigator 1 Incyte Corporation $57.54 08/04/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570331
Principal investigator 1 Incyte Corporation $57.54 08/04/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570337
Principal investigator 1 Incyte Corporation $57.54 08/04/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570343
Principal investigator 1 Incyte Corporation $57.54 08/04/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570347
Principal investigator 1 Incyte Corporation $1,952.00 08/04/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570393
Principal investigator 1 Incyte Corporation $1,952.00 08/04/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570398
Principal investigator 1 Incyte Corporation $1,952.00 08/04/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570403
Principal investigator 1 Incyte Corporation $148.00 08/01/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240498051
Principal investigator 1 Incyte Corporation $164.00 08/01/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240498055
Principal investigator 1 Incyte Corporation $74.00 08/01/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240498059
Principal investigator 1 Incyte Corporation $2,960.00 07/22/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240498012
Principal investigator 1 Incyte Corporation $1,584.30 07/18/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570047
Principal investigator 1 Incyte Corporation $497.00 07/18/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570070
Principal investigator 1 Incyte Corporation $497.00 07/18/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570075
Principal investigator 1 Incyte Corporation $7,023.00 07/17/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240498016
Principal investigator 1 Incyte Corporation $412.30 07/17/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240570998
Principal investigator 1 Incyte Corporation $436.00 07/09/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240498063
Principal investigator 1 Incyte Corporation $210.00 07/09/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570140
Principal investigator 1 Incyte Corporation $110.00 07/09/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570146
Principal investigator 1 Incyte Corporation $2,667.00 07/09/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570159
Principal investigator 1 Incyte Corporation $385.00 07/09/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570173
Principal investigator 1 Incyte Corporation $110.00 07/09/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570178
Principal investigator 1 Incyte Corporation $336.00 07/09/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570183
Principal investigator 1 Incyte Corporation $220.00 07/09/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570197
Principal investigator 1 Incyte Corporation $165.00 07/09/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570204
Principal investigator 1 Incyte Corporation $252.00 07/09/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570209
Principal investigator 1 Incyte Corporation $2,667.00 07/09/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570410
Principal investigator 1 Incyte Corporation $1,952.00 07/09/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570415
Principal investigator 1 Incyte Corporation $70.00 07/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570191
Principal investigator 1 Incyte Corporation $150.00 07/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570227
Principal investigator 1 Incyte Corporation $220.00 07/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570352
Principal investigator 1 Incyte Corporation $189.00 07/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570375
Principal investigator 1 Incyte Corporation $55.00 07/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570386
Principal investigator 1 Incyte Corporation $2,511.30 06/25/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569493
Principal investigator 1 Incyte Corporation $1,720.00 06/25/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569788
Principal investigator 1 Incyte Corporation $379.00 06/23/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240498047
Principal investigator 1 Incyte Corporation $165.00 06/23/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569337
Principal investigator 1 Incyte Corporation $100.00 06/23/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569487
Principal investigator 1 Incyte Corporation $140.00 06/23/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569499
Principal investigator 1 ABBVIE INC. $1,500.00 06/12/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 1202491205
Principal investigator 1 ABBVIE INC. $1,000.00 06/12/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 1202491207
Principal investigator 1 Incyte Corporation $1,952.00 06/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569505
Principal investigator 1 Incyte Corporation $1,952.00 06/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569899
Principal investigator 1 Incyte Corporation $1,952.00 06/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569905
Principal investigator 1 Incyte Corporation $1,952.00 06/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569911
Principal investigator 1 Incyte Corporation $1,952.00 06/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569918
Principal investigator 1 Incyte Corporation $1,952.00 06/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569923
Principal investigator 1 Incyte Corporation $1,952.00 06/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569930
Principal investigator 1 Incyte Corporation $1,952.00 06/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569937
Principal investigator 1 Incyte Corporation $24.72 06/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569711
Principal investigator 1 Incyte Corporation $15.45 06/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569728
Principal investigator 1 Incyte Corporation $32.88 06/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569732
Principal investigator 1 Incyte Corporation $98.72 06/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569751
Principal investigator 1 Incyte Corporation $17.01 06/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569757
Principal investigator 1 Incyte Corporation $32.88 06/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569764
Principal investigator 1 Incyte Corporation $48.54 06/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569770
Principal investigator 1 Incyte Corporation $1.24 06/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569775
Principal investigator 1 Incyte Corporation $114.50 06/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569782
Principal investigator 1 Incyte Corporation $135.40 06/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569981
Principal investigator 1 Incyte Corporation $32.88 06/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570027
Principal investigator 1 Incyte Corporation $32.88 06/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570037
Principal investigator 1 Incyte Corporation $150.00 06/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569523
Principal investigator 1 Incyte Corporation $126.00 06/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569531
Principal investigator 1 Incyte Corporation $220.00 06/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569809
Principal investigator 1 Incyte Corporation $1,606.45 05/28/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240570993
Principal investigator 1 Incyte Corporation $385.00 05/21/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569341
Principal investigator 1 Incyte Corporation $150.00 05/21/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569357
Principal investigator 1 Incyte Corporation $252.00 05/21/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569374
Principal investigator 1 Incyte Corporation $100.00 05/21/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569390
Principal investigator 1 Incyte Corporation $2,322.00 05/21/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569402
Principal investigator 1 Incyte Corporation $2,580.00 05/21/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569409
Principal investigator 1 ABBVIE INC. $2,480.70 05/07/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERM LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202482745
Principal investigator 1 Incyte Corporation $2,146.00 05/07/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569396
Principal investigator 1 Incyte Corporation $1,952.00 05/07/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569944
Principal investigator 1 Incyte Corporation $1,952.00 05/07/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569948
Principal investigator 1 Incyte Corporation $1,952.00 05/07/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569956
Principal investigator 1 Incyte Corporation $2,146.00 05/07/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570017
Principal investigator 1 ABBVIE INC. $1,482.20 05/06/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202481425
Principal investigator 1 Incyte Corporation $4,638.00 05/02/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240497989
Principal investigator 1 Incyte Corporation $1,400.00 05/02/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240497993
Principal investigator 1 Incyte Corporation $1,763.00 05/02/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240497999
Principal investigator 1 Incyte Corporation $2,037.00 05/02/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240498003
Principal investigator 1 Incyte Corporation $11,005.00 05/02/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240498007
Principal investigator 1 Incyte Corporation $385.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569233
Principal investigator 1 Incyte Corporation $220.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569239
Principal investigator 1 Incyte Corporation $55.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569245
Principal investigator 1 Incyte Corporation $280.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569252
Principal investigator 1 Incyte Corporation $70.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569257
Principal investigator 1 Incyte Corporation $55.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569263
Principal investigator 1 Incyte Corporation $280.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569301
Principal investigator 1 Incyte Corporation $100.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569319
Principal investigator 1 Incyte Corporation $55.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569352
Principal investigator 1 Incyte Corporation $165.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569362
Principal investigator 1 Incyte Corporation $220.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569380
Principal investigator 1 Incyte Corporation $2,734.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569416
Principal investigator 1 Incyte Corporation $126.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569422
Principal investigator 1 Incyte Corporation $45.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569429
Principal investigator 1 Incyte Corporation $80.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569437
Principal investigator 1 Incyte Corporation $337.80 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569445
Principal investigator 1 Incyte Corporation $168.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569450
Principal investigator 1 Incyte Corporation $140.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569456
Principal investigator 1 Incyte Corporation $143.30 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569462
Principal investigator 1 Incyte Corporation $70.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569468
Principal investigator 1 Incyte Corporation $300.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569474
Principal investigator 1 Incyte Corporation $200.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569479
Principal investigator 1 Incyte Corporation $24.66 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569620
Principal investigator 1 Incyte Corporation $5.30 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569624
Principal investigator 1 Incyte Corporation $24.66 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569677
Principal investigator 1 Incyte Corporation $6.36 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569698
Principal investigator 1 Incyte Corporation $124.54 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569704
Principal investigator 1 Incyte Corporation $114.50 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569716
Principal investigator 1 Incyte Corporation $74.04 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569722
Principal investigator 1 Incyte Corporation $45.80 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569738
Principal investigator 1 Incyte Corporation $54.76 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569744
Principal investigator 1 Incyte Corporation $100.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569813
Principal investigator 1 Incyte Corporation $110.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569818
Principal investigator 1 Incyte Corporation $110.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569824
Principal investigator 1 Incyte Corporation $105.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569830
Principal investigator 1 Incyte Corporation $420.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569856
Principal investigator 1 Incyte Corporation $140.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569871
Principal investigator 1 Incyte Corporation $140.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569879
Principal investigator 1 Incyte Corporation $140.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569886
Principal investigator 1 Incyte Corporation $165.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569961
Principal investigator 1 Incyte Corporation $165.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569967
Principal investigator 1 Incyte Corporation $165.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569973
Principal investigator 1 Incyte Corporation $80.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569987
Principal investigator 1 Incyte Corporation $24.66 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569991
Principal investigator 1 Incyte Corporation $24.66 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569998
Principal investigator 1 Incyte Corporation $220.00 05/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570021
Principal investigator 1 ABBVIE INC. $90.00 04/29/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202479833
Principal investigator 1 Incyte Corporation $1,459.20 04/28/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240570982
Principal investigator 1 Amgen Inc. $69,406.00 04/24/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICAL RESEARCH
A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who Are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies No dispute reported 06/30/2026 1246638680
Principal investigator 1 Amgen Inc. $20,028.00 04/24/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICAL RESEARCH
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246638682
Principal investigator 1 Incyte Corporation $63.00 04/23/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569272
Principal investigator 1 Incyte Corporation $40.00 04/23/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569307
Principal investigator 1 Incyte Corporation $55.00 04/23/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569369
Principal investigator 1 Incyte Corporation $5,948.90 04/08/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240570988
Principal investigator 1 Incyte Corporation $2,146.00 04/07/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569280
Principal investigator 1 Incyte Corporation $1,952.00 04/07/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569285
Principal investigator 1 Incyte Corporation $2,667.00 04/07/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569293
Principal investigator 1 Incyte Corporation $2,089.00 04/07/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569312
Principal investigator 1 Incyte Corporation $1,952.00 04/07/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569331
Principal investigator 1 Incyte Corporation $1,952.00 04/07/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569862
Principal investigator 1 Incyte Corporation $1,952.00 04/07/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569867
Principal investigator 1 Incyte Corporation $2,089.00 04/07/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570042
Principal investigator 1 Incyte Corporation $2,734.00 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569325
Principal investigator 1 Incyte Corporation $1,497.30 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569346
Principal investigator 1 Incyte Corporation $123.40 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569511
Principal investigator 1 Incyte Corporation $36.45 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569516
Principal investigator 1 Incyte Corporation $1.55 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569537
Principal investigator 1 Incyte Corporation $42.40 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569542
Principal investigator 1 Incyte Corporation $31.80 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569549
Principal investigator 1 Incyte Corporation $74.20 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569555
Principal investigator 1 Incyte Corporation $114.50 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569560
Principal investigator 1 Incyte Corporation $80.90 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569566
Principal investigator 1 Incyte Corporation $60.75 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569573
Principal investigator 1 Incyte Corporation $127.20 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569579
Principal investigator 1 Incyte Corporation $148.40 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569584
Principal investigator 1 Incyte Corporation $41.10 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569590
Principal investigator 1 Incyte Corporation $63.60 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569597
Principal investigator 1 Incyte Corporation $84.80 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569605
Principal investigator 1 Incyte Corporation $59.74 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569612
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569631
Principal investigator 1 Incyte Corporation $406.20 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569639
Principal investigator 1 Incyte Corporation $21.52 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569645
Principal investigator 1 Incyte Corporation $32.28 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569650
Principal investigator 1 Incyte Corporation $26.90 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569657
Principal investigator 1 Incyte Corporation $143.10 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569663
Principal investigator 1 Incyte Corporation $159.00 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569667
Principal investigator 1 Incyte Corporation $185.50 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569672
Principal investigator 1 Incyte Corporation $21.20 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569683
Principal investigator 1 Incyte Corporation $127.20 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569689
Principal investigator 1 Incyte Corporation $201.40 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569694
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569796
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569802
Principal investigator 1 Incyte Corporation $186.81 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569833
Principal investigator 1 Incyte Corporation $41.10 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569837
Principal investigator 1 Incyte Corporation $41.10 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569845
Principal investigator 1 Incyte Corporation $41.10 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569849
Principal investigator 1 Incyte Corporation $109.52 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569892
Principal investigator 1 Incyte Corporation $21.52 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570005
Principal investigator 1 Incyte Corporation $21.52 04/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240570009
Principal investigator 1 Incyte Corporation $998.45 03/19/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240570833
Principal investigator 1 Eli Lilly and Company $15,719.65 03/18/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1187875733
Principal investigator 1 Incyte Corporation $1,952.00 03/12/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569049
Principal investigator 1 Incyte Corporation $2,107.00 03/12/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569156
Principal investigator 1 Incyte Corporation $2,107.00 03/12/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569162
Principal investigator 1 ABBVIE INC. $2,139.00 03/07/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERM LLC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202461977
Principal investigator 1 Incyte Corporation $2,734.00 03/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569037
Principal investigator 1 Incyte Corporation $1,325.30 03/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569056
Principal investigator 1 Incyte Corporation $1,720.00 03/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569063
Principal investigator 1 Incyte Corporation $251.90 03/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569083
Principal investigator 1 Incyte Corporation $64.72 03/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569089
Principal investigator 1 Incyte Corporation $123.40 03/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569095
Principal investigator 1 Incyte Corporation $41.10 03/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569107
Principal investigator 1 Incyte Corporation $19.08 03/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569132
Principal investigator 1 Incyte Corporation $270.80 03/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569180
Principal investigator 1 Incyte Corporation $41.10 03/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569209
Principal investigator 1 Incyte Corporation $41.10 03/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569217
Principal investigator 1 Incyte Corporation $41.10 03/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569222
Principal investigator 1 Incyte Corporation $1,720.00 03/03/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569227
Principal investigator 1 Incyte Corporation $2,089.00 02/19/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240568971
Principal investigator 1 Incyte Corporation $2,911.00 02/19/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240568995
Principal investigator 1 Incyte Corporation $2,911.00 02/19/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569005
Principal investigator 1 Incyte Corporation $1,952.00 02/19/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569029
Principal investigator 1 Incyte Corporation $2,146.00 02/19/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569149
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $13,569.32 02/14/2025 Non-covered Recipient Entity
Academic Alliance In Dermatology
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1235999415
Principal investigator 1 ABBVIE INC. $3,991.95 02/06/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERM LLC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202449840
Principal investigator 1 Incyte Corporation $27.48 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570839
Principal investigator 1 Incyte Corporation $9.90 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570843
Principal investigator 1 Incyte Corporation $3.43 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570847
Principal investigator 1 Incyte Corporation $89.31 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570850
Principal investigator 1 Incyte Corporation $1.47 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570857
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570862
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570869
Principal investigator 1 Incyte Corporation $5.94 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570874
Principal investigator 1 Incyte Corporation $29.52 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570880
Principal investigator 1 Incyte Corporation $2.94 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570886
Principal investigator 1 Incyte Corporation $120.06 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570894
Principal investigator 1 Incyte Corporation $88.17 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570900
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570906
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570912
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570916
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570923
Principal investigator 1 Incyte Corporation $22.29 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570929
Principal investigator 1 Incyte Corporation $180.09 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570934
Principal investigator 1 Incyte Corporation $6.76 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570941
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570947
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570954
Principal investigator 1 Incyte Corporation $88.17 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570960
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570963
Principal investigator 1 Incyte Corporation $9.90 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570967
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570973
Principal investigator 1 Incyte Corporation $2.94 02/06/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240570978
Principal investigator 1 ABBVIE INC. $1,690.10 02/05/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
M19-973 - Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202446316
Principal investigator 1 Eli Lilly and Company $121,934.00 02/05/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1187872251
Principal investigator 1 Incyte Corporation $1,427.85 02/05/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240571062
Principal investigator 1 Amgen Inc. $13,537.93 01/30/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH - TAMPA
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246645863
Principal investigator 1 Incyte Corporation $1,720.00 01/27/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240568880
Principal investigator 1 Incyte Corporation $1,871.00 01/27/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240568886
Principal investigator 1 Incyte Corporation $1,454.45 01/27/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569070
Principal investigator 1 Incyte Corporation $2,089.00 01/17/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240568891
Principal investigator 1 Incyte Corporation $1,952.00 01/17/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240568897
Principal investigator 1 Incyte Corporation $1,952.00 01/17/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240568902
Principal investigator 1 Incyte Corporation $2,107.00 01/17/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240568907
Principal investigator 1 Incyte Corporation $2,107.00 01/17/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240568914
Principal investigator 1 Incyte Corporation $2,107.00 01/17/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240568921
Principal investigator 1 Incyte Corporation $2,146.00 01/17/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240568934
Principal investigator 1 Incyte Corporation $2,911.00 01/17/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240568947
Principal investigator 1 Incyte Corporation $2,089.00 01/17/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240568952
Principal investigator 1 Incyte Corporation $1,952.00 01/17/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240568959
Principal investigator 1 Incyte Corporation $2,107.00 01/17/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240568966
Principal investigator 1 Incyte Corporation $2,089.00 01/17/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569199
Principal investigator 1 Incyte Corporation $2,089.00 01/17/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569205
Principal investigator 1 Incyte Corporation $2,973.50 01/17/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240571056
Principal investigator 1 Incyte Corporation $2,580.00 01/15/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240568928
Principal investigator 1 Incyte Corporation $1,720.00 01/15/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240568940
Principal investigator 1 Incyte Corporation $1,871.00 01/15/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569168
Principal investigator 1 Incyte Corporation $1,871.00 01/15/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569174
Principal investigator 1 Incyte Corporation $1,720.00 01/15/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569185
Principal investigator 1 Incyte Corporation $1,145.90 01/15/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569192
Principal investigator 1 Novartis Pharmaceuticals Corporation $36.65 01/15/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1190304551
Principal investigator 1 ARGENX US, INC. $39.90 01/10/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid No dispute reported 06/30/2026 1237144624
Principal investigator 1 Incyte Corporation $150.00 01/08/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240568976
Principal investigator 1 Incyte Corporation $220.00 01/08/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240568983
Principal investigator 1 Incyte Corporation $110.00 01/08/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240568989
Principal investigator 1 Incyte Corporation $165.00 01/08/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569010
Principal investigator 1 Incyte Corporation $30.00 01/08/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569015
Principal investigator 1 Incyte Corporation $80.00 01/08/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569021
Principal investigator 1 Incyte Corporation $126.00 01/08/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569138
Principal investigator 1 Incyte Corporation $126.00 01/08/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569145
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $50,006.14 01/03/2025 Non-covered Recipient Entity
Academic Alliance In Dermatology
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1235999413
Principal investigator 1 ABBVIE INC. $1,611.90 01/02/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERM LLC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202436190
Principal investigator 1 ABBVIE INC. $1,734.13 01/02/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
M16-045 - Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202436194
Principal investigator 1 Amgen Inc. $47,416.18 01/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH - TAMPA
A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who Are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies No dispute reported 06/30/2026 1246645860
Principal investigator 1 Incyte Corporation $14.58 01/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569034
Principal investigator 1 Incyte Corporation $229.00 01/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569044
Principal investigator 1 Incyte Corporation $62.27 01/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569078
Principal investigator 1 Incyte Corporation $54.76 01/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569101
Principal investigator 1 Incyte Corporation $32.36 01/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569115
Principal investigator 1 Incyte Corporation $1.86 01/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569120
Principal investigator 1 Incyte Corporation $270.80 01/02/2025 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240569126